Riverbridge Partners LLC Sells 45,878 Shares of Repligen Co. (NASDAQ:RGEN)

Riverbridge Partners LLC trimmed its holdings in shares of Repligen Co. (NASDAQ:RGEN) by 9.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 455,098 shares of the biotechnology company’s stock after selling 45,878 shares during the period. Riverbridge Partners LLC owned about 0.81% of Repligen worth $65,507,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Envestnet Asset Management Inc. raised its stake in shares of Repligen by 0.7% in the second quarter. Envestnet Asset Management Inc. now owns 108,741 shares of the biotechnology company’s stock valued at $13,708,000 after buying an additional 741 shares during the period. Dimensional Fund Advisors LP raised its stake in Repligen by 39.4% in the 2nd quarter. Dimensional Fund Advisors LP now owns 429,524 shares of the biotechnology company’s stock valued at $54,149,000 after acquiring an additional 121,305 shares during the period. Renaissance Technologies LLC purchased a new stake in Repligen during the second quarter valued at about $5,320,000. Vanguard Personalized Indexing Management LLC boosted its position in Repligen by 3.7% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 5,125 shares of the biotechnology company’s stock worth $646,000 after purchasing an additional 184 shares during the period. Finally, Hsbc Holdings PLC increased its stake in shares of Repligen by 14.5% in the second quarter. Hsbc Holdings PLC now owns 14,178 shares of the biotechnology company’s stock worth $1,785,000 after purchasing an additional 1,791 shares in the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Repligen Stock Down 0.6 %

Repligen stock opened at $166.84 on Thursday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. The business has a 50-day simple moving average of $149.17 and a 200 day simple moving average of $145.43. Repligen Co. has a 52 week low of $113.50 and a 52 week high of $211.13.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.43 EPS for the quarter, topping the consensus estimate of $0.34 by $0.09. The company had revenue of $154.87 million during the quarter, compared to analyst estimates of $153.34 million. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. Repligen’s revenue was up 9.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.23 earnings per share. As a group, sell-side analysts predict that Repligen Co. will post 1.54 EPS for the current fiscal year.

Wall Street Analyst Weigh In

RGEN has been the topic of a number of recent research reports. Canaccord Genuity Group assumed coverage on shares of Repligen in a research note on Tuesday, December 17th. They set a “hold” rating and a $165.00 price target on the stock. StockNews.com raised shares of Repligen from a “sell” rating to a “hold” rating in a report on Friday, January 3rd. Canaccord Genuity Group initiated coverage on Repligen in a report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price target for the company. Wolfe Research initiated coverage on Repligen in a research note on Thursday, November 14th. They set a “peer perform” rating on the stock. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $205.00 target price on shares of Repligen in a research note on Thursday, September 26th. Six investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, Repligen presently has an average rating of “Moderate Buy” and a consensus target price of $185.20.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.